Categories: All postsAnalysts

QHR is a “compelling opportunity” for investors, says Mackie’s Voci

QHR CEO Al Hildebrandt was the winner of Cantech Letter’s 2013 TSXV Tech Executive of the Year.

Despite a recent dip from highs, shares of QHR Technologies (QHR Technologies Stock Quote, Chart, News: TSXV:QHR) have had a nice year-long run. But Mackie Research Capital analyst Massimo Voci says there is still a lot of upside in the Kelowna-based healthcare tech player.

This morning, Voci initiated coverage of QHR with a BUY rating and a one-year target of $1.75, implying a more than 40% return over yesterday’s closing price. He says QHR offers a “compelling opportunity” for investors because it operates in a rapidly growing space, has a history of profitability and high levels of recurring revenue, yet trades at a valuation he believes is discounted.

Voci says the Electronic Medical Records space is fragmented and QHR is well positioned to grow as it enters the U.S. market because it has a proven ability to grow its EMR business organically and through acquisition, and the company is now cashed up, with more than $15-million in the bank.

Much of the that cash came from the December sale of QHR’s Enterprise Management Solutions division for $20-million. Voci says he liked that move because the EMS business contributed scale and profitability, but it did not have growth. He says following the sale QHR’s margins may decline in the short termto about 10%, but the company should be able to grow these to 15% by fiscal 2015, towards management’s ultimate goal of 20%.

With EMR now constituting the vast majority of QHR’s business, Voci looked at the bigger picture on its adoption in markets the company is addressing. He notes that Canada is actually a laggard compared to places like the United Kingdom, Netherlands, Norway and Australia, where adoption exceeds 90%. Adoption in Canada grew from 37% to 56% from 2009 to 2012, according to one survey. The Mackie Research Capital analyst believes QHR will continue to benefit from increasing adoption at home as it readies itself to enter the U.S. market.

More Cantech Analysts

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: qhr
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

2 days ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

2 days ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

2 days ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

3 days ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

4 days ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

4 days ago